New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For PFE;ENDP From The Last 14 Days
Check below for free stories on PFE;ENDP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2013
08:59 EDTPFEOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTPFEZoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information
08:04 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
08:02 EDTPFEPfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information
May 21, 2013
07:16 EDTPFEPfizer management to meet with Leerink
Subscribe for More Information
May 20, 2013
17:04 EDTPFEPfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information
May 17, 2013
11:53 EDTENDPOptions with decreasing implied volatility: SGMO ARNA CSC ENDP
Subscribe for More Information
May 16, 2013
10:03 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:55 EDTPFEBofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
08:27 EDTENDPEndo Health upgraded to Buy from Neutral at Buckingham
Buckingham upgraded Endo Health based on attractive risk/reward and expectations for a more detailed strategy from the new CEO, maybe by Q2 results. Price target remains $41.
May 13, 2013
09:27 EDTENDPEndo Health downgraded to Market Perform from Outperform at William Blair
09:25 EDTENDPOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTENDPEndo Health falls 4.8%
Endo Health is down 4.8%, or $1.67, to $33.30
08:13 EDTENDPEndo Health price target lowered to $31 from $35 at Susquehanna
Subscribe for More Information
07:49 EDTENDPFDA decision on Opana a modest positive for Impax, says Leerink
Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires.
07:45 EDTENDPEndo Health price target lowered to $36 from $42 at Stifel
Subscribe for More Information
07:32 EDTENDPEndo Health downgraded to Sell from Neutral at Lazard Capital
Subscribe for More Information
07:20 EDTENDPEndo Health price target lowered to $37 from $47 at Jefferies
Jefferies lowered its price target for Endo Health after the FDA ruled that crushable Opana generics can come to market. The firm keeps a Buy rating on the stock, saying the company's spending flexibility is underappreciated.
06:48 EDTENDPEndo Health downgraded to Fair Value from Buy at CRT Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.